TScan Therapeutics reported Q4 2025 collaboration and license revenue of USD 2.6 million (up 285.9%), with R&D expenses of USD 20.0 million and G&A expenses of USD 6.4 million. Net loss was USD 23.0 million in Q4 2025. For FY 2025, revenue was USD 10.3 million (up 266.7%), R&D expenses were USD 114.2 million, G&A expenses were USD 32.0 million, and net loss was USD 129.8 million. Cash and cash equivalents were USD 152.4 million as of Dec. 31, 2025, and TScan Therapeutics said its cash resources are expected to fund operations into the second half of 2027. On the business side, TScan Therapeutics highlighted positive updated Phase 1 ALLOHA data for lead candidate TSC-101 presented at ASH, reporting no dose-limiting toxicities and relapse-free survival and overall survival hazard ratios of 0.50 and 0.61, respectively; 3/3 (100%) treated patients reaching two-year follow-up remained relapse-free versus 1/4 (25%) in the control arm. The company also said it completed enrollment in Cohort C of the Phase 1 ALLOHA trial, with patients dosed using a commercial-ready manufacturing process, and that the FDA cleared INDs for allogeneic CD45-targeting candidates TSC-102-A01 and TSC-102-A03, with a Phase 1 study planned for the second half of 2026. TScan Therapeutics said it plans to share early Cohort C data and launch a pivotal TSC-101 trial in Q2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TScan Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603040700PRIMZONEFULLFEED9665501) on March 04, 2026, and is solely responsible for the information contained therein.